GLOBAL HEALTH INSIGHTS

Home › AMR › Child Health › UC Davis Scientific team strengthens case for Bifidobacterium in the fight against antibiotic resistance

UC Davis Scientific team strengthens case for Bifidobacterium in the fight against antibiotic resistance

icddr,b communications October 19, 2018     No Comment    

New study, co-authored by Evolve BioSystems co-founder, shows urgency of restoring disappearing bacterium to natural levels

News by Evolve BioSystems, Inc.

Children with higher levels of the beneficial bacteria, Bifidobacterium, in their gut microbiome had reduced abundance and lower frequency of antimicrobial resistance (AMR) genes, finds a new study with icddr,b.

Published in mSphere, the study led by Dr David Mills and Dr Diana Taft, was a collaboration between the University of California, Davis and icddr,b. Dr Mills is a professor in the Departments of Viticulture & Enology and Food Science & Technology at UC Davis and an Evolve BioSystems co-founder.

AMR is the ability of a microorganism to withstand an antibiotic or other antimicrobial, rendering standard treatments ineffective and raising the risk, persistence and spread of infections. The findings of the study suggest that increasing the abundance of Bifidobacterium in the infant gut is both a simple and novel approach to reducing AMR-related genes.

 

Facing down a global health crisis

AMR contributes to more than 23,000 deaths and 2 million illnesses in the U.S. annually, and antibiotic resistance in particular is cited by the World Health Organization (WHO) as “one of the biggest threats to global health, food security, and development today.”

Infants may be particularly susceptible, as the genes responsible for AMR can appear early in life when a baby’s immune system is still in development.

“Treating children with antibiotics like penicillin during their early years may increase AMR,” according to Dr Mills.

The WHO also notes that while antibiotic resistance occurs naturally, misuse of antibiotics is accelerating the process. However, the study suggests that high levels of Bifidobacterium can prevent colonization by potential AMR-related bacteria, thus protecting the infant intestine.

 

Mounting evidence supports the benefits of Bifidobacterium, but its levels are decreasing

“This study is revelatory on its own merits, but it’s also an important link in a chain of recent discoveries that have shed light on the importance of Bifidobacterium in infants,” said Dr David Kyle, chief scientific officer at Evolve BioSystems.

“Along with findings which show that infants supplemented with a specific strain of Bifidobacterium, B. infantis EVC001, showed a significant reduction in virulence factor genes and colonic mucin degradation, a clearer picture of its importance to infant—and possibly lifelong health—is emerging. We’re gaining insight at a rapid pace, and the implications are huge.”

Mills and Kyle also note, however, that while evidence mounts regarding the benefits of Bifidobacterium, research shows that its levels have been declining in the U.S. and other developed countries over the past 100 years as a possible unintended consequence of modern medical practices like antibiotics, lack of breastfeeding and C-sections.

“The results from this study strongly support the idea that infants who acquire Bifidobacterium early in life are provided some level of natural protection against AMR,” said Mills.

About Evolve BioSystems

David Mills is a Peter J. Shields Endowed Chair in the Departments of Food Science & Technology at the University of California at Davis, and co-founder of Evolve BioSystems, makers of Evivo® baby probiotic. In the last 20 years Dr Mills has published more than 180 papers, including seminal work on probiotic genomics.

Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy gut microbiome. Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the development and commercial launch of products to resolve newborn gut dysbiosis, including Evivo® for infants, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well. In addition to the landmark proof-of-concept trial, Evolve is undertaking further clinical studies to build out its suite of microbiome-based solutions.

AMR Child Health

 Previous Post

How can dialogues benefit urban health and universal health coverage?

― October 6, 2018

Next Post 

Why it is important mothers breastfeed within an hour of birth

― November 5, 2018

Author: icddr,b communications

Related Articles

Farasha Bashir ― December 5, 2020 | No Comment

Capacity Development Workshop of Health Professional on Data Analysis and Thesis Writing

icddr,b, in collaboration with Bangladesh Perinatal Society, Bangladesh Neonatal Forum, and Department of Neonatology of Bangabandhu Sheikh Mujib Medical University

Farasha Bashir ― October 5, 2020 | No Comment

Logistics distribution at OGSB Maternity Hospital for strengthening Infection Prevention and Control measures

Farasha Bashir ― September 23, 2020 | No Comment

Online workshop with newborn experts for Newborn Signal Functions

Farasha Bashir ― August 29, 2020 | No Comment

Global Fund Grant application on HIV

Farasha Bashir ― March 3, 2020 | No Comment

Feedback on Global Fund Grant application on HIV

Farasha Bashir ― February 3, 2020 | No Comment

Experts gather to take action on typhoid and cholera

Farasha Bashir ― December 11, 2019 | No Comment

RDM launches its new website

Farasha Bashir ― November 24, 2019 | No Comment

How to curb intimate partner violence? Let young boys witness gender-equality at home

Leave a Reply Cancel reply

You must be logged in to post a comment.

About Global Health Insights

Global Health Insights is an icddr,b produced and curated blog that brings to light the motivation behind the science. All opinions expressed in these articles belong to the authors and are not endorsed by icddr,b.

About icddr,b

icddr,b is a Bangladesh-based international health research institute that strives to solve key public health problems through high quality scientific research and innovation. Policy makers and practitioners utilise our evidence and expertise to improve health outcomes and prevent premature death and disability worldwide. Established more than 50 years ago, we continue to provide life-saving services to the people of Bangladesh, and to nurture the next generation of global health leaders.

Recent Posts

  • Capacity Development Workshop of Health Professional on Data Analysis and Thesis Writing
  • Logistics distribution at OGSB Maternity Hospital for strengthening Infection Prevention and Control measures
  • Online workshop with newborn experts for Newborn Signal Functions
  • Global Fund Grant application on HIV
  • Feedback on Global Fund Grant application on HIV

Subscribe

Author List

  • admin (2)
  • Aminul Islam (1)
  • Dr. K. Zaman (1)
  • Farasha Bashir (23)
  • icddr,b communications (18)
  • Liza Talukder (1)
  • M Nazim Uddin (1)
  • Monjur Ahmed (5)
  • Muhammad Asaduzzaman (2)
  • Shafiul Khan (5)
  • Sharful Islam Khan (1)
  • Tahmeed Ahmed (1)
  • Zain Ali (11)
Copyright © 2021 icddr,b. All Rights Reserved.